bupropion

(redirected from Wellbutrin xl)
Also found in: Medical.

bu·pro·pi·on

 (byo͞o-prō′pē-ŏn′)
n.
A drug, C13H18ClNO, used in its hydrochloride form for the treatment of depression and as an aid in smoking cessation. It is a weak inhibitor of norepinephrine and dopamine reuptake in the central nervous system.

[bu(tyl) + propi(ophen)on(e), a ketone (propio(nic acid) + phen(yl) + -one).]

bupropion

(bjuːˈprəʊpɪɒn)
n
an antidepressant drug used to help people stop smoking
Translations

bupropion

n bupropión m
Mentioned in ?
References in periodicals archive ?
The approved product is a generic version of Wellbutrin XL of Valeant (NYSE: VRX).
In 2007, there were complaints from patients who had been taking the 300 mg dose of an extended-release version of the popular antidepressant, Wellbutrin XL 300, and had recently switched to the generic equivalent, Budeprion XL 300, made by US-based Impax Pharmaceuticals and marketed by the Israeli generic company Teva.
The company added that the Bupropion HCl ER Tablets USP (XL) are the generic version of WELLBUTRIN XL and are indicated for the treatment of major depressive disorder (MDD).
The product is one of the five generic versions of Wellbutrin XL 300-mg tablets that have been approved by the FDA.
The affected product is Budeprion XL 300 mg, manufactured by Impax Laboratories and marketed by Teva Pharmaceuticals USA--one of the five generic versions of Wellbutrin XL 300-mg tablets that have been approved by the FDA.
Biovail (TSE: BVF) makes Wellbutrin XL, a widely prescribed anti-depressant, and Ultram ER, an extended-release formulation of an anti-pain medicine.
7 million, reflecting the sale of Wellbutrin XL in the U.
The researchers also found that they could predict whether subjects were more likely to respond to a different antidepressant, bupropion, also known as Wellbutrin XL.
GlaxoSmithKline's unique dual-acting treatment option for major depressive episodes, Wellbutrin, is currently available as a once daily extended-release tablet, Wellbutrin XL.
In addition, GSK continued to face notable exposure to generic competition in the key US market with the Wellbutrin XL, Zofran and Coreg IR brands all cited as generic sales casualties.
A lot will depend on the timing of generic competition to Wellbutrin XL, but we see no reason to change our positive view of the shares.